Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Nexgel Inc(NXGL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NXGL
09/28/2026: NXGL (1-star) is currently NOT-A-BUY. Pass it for now.
Nexgel Inc is a medical technology company specializing in high-water-content, electron-beam cross-linked hydrogel products for medical and cosmetic applications. Its primary strength lies in its proprietary manufacturing technology, which offers unique material properties that are attractive for advanced wound care and transdermal drug delivery. The company's growth story is built on transitioning from an R&D-heavy phase to a commercial supplier for both medical firms and consumer brands. However, investors face risks regarding intense competition, lack of current profitability, and potential execution challenges in scaling operations. This stock is generally suited for growth-oriented investors who can tolerate significant volatility, and progress in securing long-term strategic partnerships is a key development to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Nexgel offers growth potential in a specialized niche but faces significant early-stage execution risks. |
| Momentum investor | Weak fit | The stock lacks consistent, high-volume upward momentum and is susceptible to market sentiment shifts. |
| Value investor | Weak fit | The company is not currently profitable, making traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | Nexgel does not pay a dividend and is not expected to do so in the near term. |
| Low-risk investor | Weak fit | The high volatility and early-stage nature of the company make it unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech/medtech stocks often experience sharp price swings based on news cycles. |
| Valuation risk | Medium / high | Without stable earnings, the stock price is heavily reliant on future growth expectations. |
| Competition risk (Medical Devices) | High | Established players can easily outspend and out-distribute a small company like Nexgel. |
| Business quality | Medium | The business relies on proprietary technology, but commercial viability is still being proven. |
| Dividend income | Low / none | Investors should not rely on this stock for income. |
| Execution risk | High | Success depends on manufacturing efficiency and securing long-term customer contracts. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -30.53% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.70M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1.3M shares | Beta 0.75 | 52 Weeks Range 0.16 - 2.89 | Updated Date 09/27/2026 |
52 Weeks Range 0.16 - 2.89 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Advanced Wound Care | Hydrogel dressings and wound care products. | Selling medical-grade supplies to healthcare providers. |
| Consumer/Cosmetics | Facial masks and personal care products. | Manufacturing products for beauty brands. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1.38 | Enterprise Value 9.50M | Price to Sales(TTM) 0.14 |
Enterprise Value 9.50M | Price to Sales(TTM) 0.14 | ||
Enterprise Value to Revenue 0.79 | Enterprise Value to EBITDA -0.85 | Shares Outstanding 9.75M | Shares Floating 7.70M |
Shares Outstanding 9.75M | Shares Floating 7.70M | ||
Percent Insiders 14.02 | Percent Institutions 13.67 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Nexgel Inc
Exchange NASDAQ | Headquarters Langhorne, PA, United States | ||
IPO Launch date 2021-12-22 | Interim CEO & Director Mr. Brian J. Kieser C.P.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 19 | Website https://nexgel.com |
Full time employees 19 | Website https://nexgel.com | ||
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.